Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.

ABSTRACT: Ongoing emergence of SARS-CoV-2 Omicron subvariants and their rapid worldwide spread pose a threat to public health. From November 2022 to February 2023, newly emerged Omicron subvariants, including BQ.1.1, BF.7, BA.5.2, XBB.1, XBB.1.5, and BN.1.9, became prevalent global strains (>5% global prevalence). These Omicron subvariants are resistant to several therapeutic antibodies. Thus, the antiviral activity of current drugs such as remdesivir, molnupiravir, and nirmatrelvir, which target highly conserved regions of SARS-CoV-2, against newly emerged Omicron subvariants need to be evaluated. We assessed the antiviral efficacy of the drugs using the half-maximal inhibitory concentration (IC₅₀) against human isolates of 23 Omicron subvariants and four former SARS-CoV-2 variants of co

SUBMITTER: Cho J 

PROVIDER: S-EPMC10118056 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature